Close Menu

NEW YORK (GenomeWeb) – Personalis this week said that the Parker Institute for Cancer Immunotherapy will use Personalis' ImmunoID Next cancer immunogenomics platform to investigate biomarkers of response to immunotherapies in clinical trial participants. The trials include melanoma, pancreatic, and all-comer solid tumor patients treated with checkpoint inhibitors, either as monotherapy or in combination with other cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.